Advanced searches left 3/3

Everolimus - Europe PMC

Summarized by Plex Scholar
Last Updated: 07 August 2022

* If you want to update the article please login/register

Vascular healing in high-bleeding-risk patients at 3-month after everolimus-eluting stent versus biolimus A9-coated stent implantation: insights from analysis of optical coherence tomography and coronary angioscopy.

We prospectively reviewed 38 HBR patients with coronary artery disease who underwent everolimus-eluting stent implantation or drug-coated stent implantation. According to CAS results, mean yellow color grade was much higher with EES than with DCS. Both groups had well-apposed struts with neointimal coverage, and the majority of the mean neointimal area was similar between EES and DCS, according to OCT results. With EES and DCS, the number of uncovered struts was significantly lower than with DCS, but with EES than with DCS, the frequency of malapposed struts was much greater than with EES than with DCS, although with EES was much higher than with DCS, although with EES it was much higher than with DCS.

Source link: https://europepmc.org/article/MED/35918588


Safety and Clinical Performance of Biodegradable Polymer-Coated Ultra-Thin Everolimus-Eluting Stents in "Real-World" Patients: A Multicenter Registry (PERFORM-EVER).

Background Tetrilimus is a biodegradable polymer-coated everolimus-eluting stent with a cobalt-chromium stent platform and ultra-thin strut thickness. In "real-world" clinical research, we aimed to publish 1-year safety and clinical results of Tetrilimus everolimus-eluting stent in patients with coronary artery disease. Patients from July-2015 to October-2016 at four research centers were analyzed, including patients from "real-world" and Tetrilimus everolimuseluting stent. Primary endpoint was a 1-year incidence of target lesion failure, which was defined as a composite endpoint of cardiac death, myocardial infarction, and target lesion revascularization by percutaneous or surgical methods. Target lesion revascularizations were 3. 7% at one-year follow-up, with 9 cardiac deaths, 8 myocardial infarctions, and 5 target lesion revascularizations. At a 1-year follow-up, there were 5 cases of suspected stent thrombosis and four cases of potential thrombosis.

Source link: https://europepmc.org/article/MED/35924288


Everolimus for Treating Hormone Receptor-positive Metastatic Breast Cancer Previously Treated With Cyclin-dependent Kinase 4/6 Inhibitors.

Background/aim The first and second-line treatments for hormone receptor-positive or human epidermal growth factor receptor 2 (negative metastatic and recurrent breast cancers) have become the gold standard of care. Though CDK 4/6 inhibitors can dramatically enhance progression-free survival, there is no concrete evidence of their post-treatment effects, although CDK 4/6 inhibitors can prolong progression-free life. This research was aimed at determining neverolimus' efficacy as a post-treatment therapy option in clinical settings following CDK4/6 inhibitor administration. Patients and methods Thirteen patients who received Everolimus as a post-treatment after receiving CDK4/6 inhibitor therapy from December 2017 to July 2021 were retrospectively reviewed, including thirteen patients. According to respectively, the overall response rate and clinical care rate were 15. 3% and 42. 2%. Conclusions Given that there is a mechanism of resistance to CDK4/6 inhibitors, everolimus would be a useful post-treatment for HR+ or recurrent breast cancers treated with CDK4/6 inhibitors in clinical settings.

Source link: https://europepmc.org/article/MED/35896230


Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial.

Preclinical synergistic anticancer therapy by the mTOR inhibitor everolimus, as well as the oral glutaminase inhibitor telaglenastat, led to preclinical outcomes and efficacy in a phase I trial of 2L+ renal cell carcinomas. In patients with persistent/metastatic RCC in the 3L+ setting, this research compared telaglenastat plus everolimus to placebo plus everolimus. median PFS for TelaE was 3. 8 months versus 1. 9 months for PboE [HR, 0. 64; 95% confidence interval, 0. 34-1. 20]; one-sided P = 0. 079] at a median follow-up of 7. 5 months. One TelaE patient had partial response but 26 had stable disease. PboE had SD in eleven patients. In patients with mRCC who were previously treated with TKIs and checkpoint inhibitors, TelaE was well tolerated and increased PFS versus PboE.

Source link: https://europepmc.org/article/MED/35576438


Everolimus Concentration in Saliva to Predict Stomatitis: A Feasibility Study in Patients with Cancer.

Background Toxion Stomatitis, a patient treated with everolimus, is a serious threat to the quality of life. Methods Saliva and whole blood samples were collected from patients with cancer who were treated with everolimus in the dosage of either 10 mg once a day or 5 mg twice a day. A published population pharmacokinetic model was expanded with the everolimus concentration in saliva to investigate any relationship between everolimus in the blood and saliva to see any connection. The association between stomatitis outbreak and the everolimus concentration in saliva was investigated later. Everolimus' salivary content increased in patients with stomatitis, 1 hour postdose - 1 hour postdose. Conclusions Quantification of Everolimus Concentration in saliva was feasible and revealed a nonsignificant relationship between everolimus concentration in the saliva and the occurrence of stomatitis, according to the researchers.

Source link: https://europepmc.org/article/MED/35094002


Recurrent Cytomegalovirus Infection Controlled by the Introduction of Everolimus in a Simultaneous Pancreas-Kidney Transplantation Recipient: A Case Report.

As one of the immunosuppressive drug therapies, the use of a mammalian rapamycin inhibitors resulted in decreased rates of CMV infection in the field of solid organ transplantation. However, little is known about the use of mTORi in pancreas transplantation. We describe a case of recurrent CMV disease in SPK that was largely attributed to a TAC-based immunosuppression program. On the 13th day of surgery, Graft duodenal perforation was reported, and after long-term absces drainage therapy, graft duodenal resection was performed. However, there was a regular need for granulocyte-colony stimulating factor therapy due to recurrent febrile neutropenia caused by cytopenia as a side effect of valganciclovir. The aim of lowering the dose of TAC and mycophenolate mofetil was originally intended to reduce recurrent CMV viremia, and everolimus was introduced with the intention of reducing the dose of TAC and mycophenolate mofetil.

Source link: https://europepmc.org/article/MED/35914968


Comparison of MECHANISM of early and late vascular responses following treatment of ST-elevation acute myocardial infarction with two different everolimus-eluting stents: a randomized controlled trial of biodegradable versus durable polymer stents.

The early and mid-term arterial healing profile of biodegradable polymer-coated stents in ST-segment elevation myocardial infarction culprit lesions is unclear, particularly in ST-segment elevation myocardial infarction culprit lesions. This research was designed to evaluate early and mid-term arterial regeneration in STEMI patients with durable polymer-coated everolimus-eluting stents and BP-EES. P non-inferiority = 0. 0756), the primary endpoint of %covered struts at 2 weeks in BP-EES and 72. 3 percent in DP-EES and 73% in DP-EES] [risk difference - 0. 9 percent, lower limit of one-sided 95% confidence interval] - 4. 7 percent; lowest endpoint of one-sided 95% confidence interval - 5. 6] BP-EES had a significantly higher average neointimal area with a significantly lower average intra-stent tissue unevenness score than DP-EES at 12 months, indicating more uniform neointimal coverage with BP-EES at 12 months. JRCTs022180024 w. jrct. google. com/en-latest-detail/jRCTs022180024 jRCTs022180024 https://jrct. org/en-latest-detail/jRCTs022180024 http://jrct. com/en-latest-detail/jRCTs022180024: jRCTs02212180024 jRCTs0221202180024.

Source link: https://europepmc.org/article/MED/35896895


Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma.

Patient and methods HRQOL data were collected during a multicenter, randomized, open-label phase II research comparing the safety and effectiveness of two different starting doses of lenvatinib in combination with everolimus following one prior vascular endothelial growth factor-targeted therapy. Baseline characteristics of the 343 participants randomly assigned to 18 mg lenvatinib and 14 mg lenvatinib were both balanced. Change from baseline was expected for the 18 mg group over the 14 mg group for the FKSI-DRS and the majority of EORTC QLQ-C30 scales, according to Least-squares mean estimates for change from baseline, but treatment differences did not exceed the minimally relevant thresholds. For the most scales, the 18 mg group was longer among participants than those in the 14 mg group. Participants who received an 18 mg lenvatinib starting dose had high HRQOL scores and longer TTD on most scales, compared to those who received a 14 mg starting dose.

Source link: https://europepmc.org/article/MED/35881028


Sotorasib associated with tacrolimus and everolimus: A significant drug interaction in lung transplant patients.

Regular adjustment of the dosage to the appropriate level is required for the proper treatment of immunosuppressors in solid organ transplantation. The introduction of sotorasib, a drug used for metastatic pulmonary adenocarcinoma, in a 72-year-old lung transplanted man who was treated with tacrolimus and everolimus for the long run, left his residual immunosuppressor levels unbalanced.

Source link: https://europepmc.org/article/MED/35901952


Successful implantation of a novel polymer-free everolimus-eluting stent using nitrogen-doped titanium dioxide film with good patency on follow-up angiography: A case report.

We designed the TIGEREVOLUTION stent with a cobalt-chromium alloy-based stent platform, which has demonstrated good biocompatibility and was resistant to these issues. As this stent is not coated with polymer, it is expected to reduce the risk of stent thrombosis. Diagnosis CAG's mid-portion of the right coronary artery revealed significant stenosis, with a minimum lumen area of 1. 08mm2 on optical coherence tomography. Intervention Percutaneous coronary Intervention was carried out with the introduction of a new 3. 5 mm polymer-free everolimus-eluting stent with nitrogen-doped titanium dioxide film from nitrogen-doped titanium dioxide film. The patient was discharged safely and uneventfully after undergoing post-percutaneous coronary intervention OCT showed promising stent growth and apposition, and apposition, and OCT performed well, and OCT showed good stent formation and apposition, and post-percutaneous coronary therapy was performed safely and uneventfully. Outcomes Eight months later, a follow-up coronary angiography published a good stent patency with no definitive signs of in-stent restenosis, with no clear signs of in-stent restnosis, despite limited stent strut coverage on OCT. Lessons We are the first case of TIGEREVOLUTION stent placement after which we report Lessons. With a follow-up OCT at 8 months, we present the first case of TIGEREVOLUTION stent implantation.

Source link: https://europepmc.org/article/MED/35866823

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions